Navigation Links
Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
Date:5/3/2012

ble bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... 11, 2011 Instacare Corp. (OTCQB: ISCR), the exclusive ... targeted at the $20 billion diabetes care marketplace, a ... for the chronically ill, and a leading developer of ... technologies, today announced that its Board of Directors has ...
... N.J., May 11, 2011 Pharmaceutical giants seeking new ... information on the pharma industry all know there,s only ... most successful and time-tested event for pharma industry leaders- ... 2011 in Parsippany, New Jersey ( www.pharmaciconference.com ). ...
Cached Medicine Technology:Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate 2Pharma Elite to Unveil Latest Industry News/Program Agenda with 70+ Expert Speakers at Exclusive Event: Pharma CI Conference, September 13-14, 2011 in New Jersey 2
(Date:5/22/2015)... May 22, 2015 “It’s like ... SLP, RAC-CT, CHHRP-QT, Vice President of Clinical Operations/Education ... important ‘language’ that impacts how care is coded ... in long term care reimbursement, operations and compliance ... and talent management, launches a new series of ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Coordinating ... a difficult process. Historically providers have not been ... payers. Starting in 2015, Medicare has paved the ... activities. Thanks to the launch of Oculus ... and health systems using the platform will now ...
(Date:5/22/2015)... May 22, 2015 Power Systems is proud ... the 2015 race season. Drobeck is in his second year ... a firefighter with the Missoula Fire Department in Missoula, MT. ... Pro in 2014. During his career, he has had 15 ... Drobeck recorded top 10 finishes in all seven of his ...
(Date:5/22/2015)... Philadelphia, PA (PRWEB) May 22, 2015 According ... as a hub for drug related death, totaling almost 2,500 ... number, as reported by state officials, totals 2,489 deaths stemming ... numbers work out, Pennsylvania loses seven people every day to ... Philadelphia has been singled out as one of the most ...
(Date:5/22/2015)... May 22, 2015 Medivo, Inc., a leader ... Rates and Genotype Results in ‘Baby Boomers’ Screened for HCV ... Nationwide Lab Test Database” at Digestive Disease Week, May 16-19, ... Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, ... Parker, MSI, along with Nancy Reau, MD from the University ...
Breaking Medicine News(10 mins):Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2
... literally the spice of life and for many people ... unthinkable. Yet just this aspect of everyday life is ... eating behaviours including changes in food preferences, faddism and ... these behaviours are linked to a loss of meaning ...
... to help later on, study suggests, , MONDAY, May ... from the breast in early infancy tend to consume ... research suggests. , This kind of self-regulation of food ... that breast-feeding protects against obesity. , "Infant self-regulation ...
... , ... Commissioner David Kessler, current Georgia Congressman Tom Price and Dr. Donald Hensrud of Mayo ... (MDPA) National Conference, October 19-21, 2010, in Atlanta, Georgia. , ... Florham Park, NJ (PRWEB) May 10, 2010 ...
... ... cancer charities through the sale of its ,breasts are beautiful, coffee table book , ... San Francisco, CA (PRWEB) May 10, ... 8 chance of contracting breast cancer, Jenny McCarthy has teamed with b for a cure ...
... ... almost 0.25 carats and worth over $700*! This diamond is perfect for setting in ... appraisal of your new gem, compliments of AllianceDiamonds.com. , ... (PRWEB) May 10, 2010 -- Certified loose diamond ...
... cancer have nearly doubled over the past two decades and ... by private health insurance and Medicaid have increased. The study ... treatments to outpatient care. Published early online in CANCER ... information could be used to prioritize future resources for treating ...
Cached Medicine News:Health News:Dementia takes away the meaning of flavors 2Health News:Breast-Fed Babies Know When to Say When 2Health News:Breast-Fed Babies Know When to Say When 3Health News:Dr. Kessler, Congressman Price & Mayo Clinic Headline Inaugural MDPA Conference 2Health News:Dr. Kessler, Congressman Price & Mayo Clinic Headline Inaugural MDPA Conference 3Health News:Jenny McCarthy - Actress, Activist, and Model - Dedicates bforacure's ‘breasts are beautiful' to Help Raise Money for Breast Cancer Charities 2Health News:Jenny McCarthy - Actress, Activist, and Model - Dedicates bforacure's ‘breasts are beautiful' to Help Raise Money for Breast Cancer Charities 3Health News:AllianceDiamonds.com Presents: Facebook Diamond Giveaway 2010 2Health News:Medical costs of cancer have nearly doubled over the past 2 decades 2
... patient serum or plasma, standards and controls are ... After a washing step, an alkaline phosphatase ... Fc region of human IgG. After another ... by a stopping step. The absorption is ...
...
...
...
Medicine Products: